Following the resolution of Eli Lilly’s tirzepatide shortage in October, the FDA has officially declared an end to the supply ...
Shares of Hims & Hers Health (NYSE:HIMS) are down about 21%, or $14. All on news the Ozempic shortage is over. Key Points ...
The use of semaglutide (Ozempic) was tied to a small risk of nonarteritic anterior ischemic optic neuropathy (NAION) in ...
WEIGHT loss jabs could raise the risk of a “potentially blinding condition” known as an “eye stroke”, researchers have warned ...
A randomized, placebo-controlled trial validates a side effect frequently observed by doctors and patients. A new study from ...
Semaglutide — the active ingredient in the brand-name meds Ozempic, Wegovy, and Rybelsus — treats type 2 diabetes and obesity ...
Semaglutide, a medication widely used for diabetes and weight loss, may offer another unexpected benefit -- it could help ...
Semaglutide's role extends beyond diabetes, aiding weight loss and offering cardiovascular protection, with ongoing research ...
Adults with type 2 diabetes may have a higher risk for developing nonarteritic anterior ischemic optic neuropathy while using ...
A recent review and meta-analysis of semaglutide studies found that this drug can significantly reduce the risk of hospitalization from heart failure and deaths from cardiovascular causes ...